1228078-65-6 ((PAR-4 Agonist Peptide, amide TFA)

PAR-4 Agonist Peptide, amide TFA;PAR-4 Agonist Peptide, amide (TFA);AY-NH2 (TFA);PAR-4-AP (TFA);AY-NH2 (TFA)PAR-4-AP (TFA);L-alanyl-L-tyrosyl-L-prolylglycyl-L-lysyl-L-phenylalaninamide,trifluoroacetatesalt;G13304;MS-31461;CS-0089115;(2S)-6-AMINO-2-(2-{[(2S)-1-[(2S)-2-[(2S)-2-AMINOPROPANAMIDO]-3-(4-HYDROXYPHENYL)PROPANOYL]PYRROLIDIN-2-YL]FORMAMIDO}ACETAMIDO)-N-[(1S)-1-CARBAMOYL-2-PHENYLETHYL]HEXANAMIDE; TRIFLUOROACETIC ACID;(2S)-N-[2-[[(2S)-6-amino-1-[[(2S)-1-amino-1-oxo-3-phenylpropan-2-yl]amino]-1-oxohexan-2-yl]amino]-2-oxoethyl]-1-[(2S)-2-[[(2S)-2-aminopropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxamide;2,2,2-trifluoroacetic acid;1228078-65-6;Ala-Tyr-Pro-Gly-Lys-Phe-NH2 trifluoroacetate salt;HY-P1309A;EX-A5576;Ala-Tyr-Pro-Gly-Lys-Phe-NH2 trifluoroacetate salt, >=98% (HPLC), solid;AKOS040763883;BGPJLFVICWHITH-HKJXYENISA-N;DA-56586;

BGPJLFVICWHITH-HKJXYENISA-N

1S/C34H48N8O7.C2HF3O2/c1-21(36)31(46)41-27(19-23-12-14-24(43)15-13-23)34(49)42-17-7-11-28(42)33(48)38-20-29(44)39-25(10-5-6-16-35)32(47)40-26(30(37)45)18-22-8-3-2-4-9-22;3-2(4,5)1(6)7/h2-4,8-9,12-15,21,25-28,43H,5-7,10-11,16-20,35-36H2,1H3,(H2,37,45)(H,38,48)(H,39,44)(H,40,47)(H,41,46);(H,6,7)/t21-,25-,26-,27-,28-;/m0./s1

FC(C(=O)O)(F)F.O=C([C@H](CC1C=CC(=CC=1)O)NC([C@H](C)N)=O)N1CCC[C@H]1C(NCC(N[C@H](C(N[C@H](C(N)=O)CC1C=CC=CC=1)=O)CCCCN)=O)=O